ArticleArchives of medical science : AMS2025
From cirrhosis to hepatogenous diabetes: risk factors and glycemic management.
Article in Archives of medical science : AMS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hepatogenous diabetes in the era of precision medicine: diagnosis, management, and future directions.Clinical and experimental medicine · 2026Review
- Differential Metabolic Dysregulations in Hepatocellular Carcinoma and Cirrhosis: Insights into Lipidomic Signatures.Biomolecules · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Our study analyzed the risk factors associated with hepatogenous diabetes (HD) and compared glycemic control under various treatment modalities. Material and methods: The multicenter study included 327 patients with HD, while 329 non-diabetic liver cirrhosis (LC) patients were selected as the control group for examining HD risk factors. Three groups of HD patients with HbA Results: The results indicated that longer disease duration of cirrhosis (OR = 1.111, 95% CI: 1.072-1.152, Conclusions: The risk factors for HD include prolonged duration of LC, vertical transmission of hepatitis B, higher Child-Pugh grade, and elevated blood triglyceride levels. A history of endoscopic treatment was found to be a protective factor. Glycemic management was substantially enhanced among patients who received insulin therapy, either alone or combined with oral hypoglycemic drugs, as opposed to those who depended solely on oral hypoglycemic agents.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.